ME01337B - Tečni preparat fsh - Google Patents
Tečni preparat fshInfo
- Publication number
- ME01337B ME01337B MEP-2011-182A MEP18211A ME01337B ME 01337 B ME01337 B ME 01337B ME P18211 A MEP18211 A ME P18211A ME 01337 B ME01337 B ME 01337B
- Authority
- ME
- Montenegro
- Prior art keywords
- pharmaceutical preparation
- liquid pharmaceutical
- preparation according
- fsh
- benzalkonium chloride
- Prior art date
Links
- 239000012669 liquid formulation Substances 0.000 title 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims abstract 18
- 239000007788 liquid Substances 0.000 claims abstract 15
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims abstract 8
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims abstract 8
- 229940028334 follicle stimulating hormone Drugs 0.000 claims abstract 7
- 229960000686 benzalkonium chloride Drugs 0.000 claims abstract 6
- 235000019445 benzyl alcohol Nutrition 0.000 claims abstract 6
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims abstract 6
- 239000003755 preservative agent Substances 0.000 claims abstract 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract 3
- 229930182817 methionine Natural products 0.000 claims abstract 3
- 238000002360 preparation method Methods 0.000 claims abstract 3
- 239000003963 antioxidant agent Substances 0.000 claims abstract 2
- 230000003078 antioxidant effect Effects 0.000 claims abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 15
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000004094 surface-active agent Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- 229920001214 Polysorbate 60 Polymers 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000005907 alkyl ester group Chemical group 0.000 claims 1
- 239000003708 ampul Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229940068977 polysorbate 20 Drugs 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 150000005846 sugar alcohols Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (15)
1.Tečni farmaceutski preparat koji obuhvata folikul-stimulirajući hormon (FSH) ili njegovu varijantu, kao i benzalkonijum hlorid i benzil alkohol kao sredstva za čuvanje.
2.Tečni farmaceutski preparat prema zahtevu 1, pri čemu je benzalkonijum hlorid prisutan u koncentraciji od 0.005 – 0.03 mg/ml i benzil alkohol je prisutan u koncentraciji od 5.0 do 12.0 mg/ml.
3.Tečni farmaceutski preparat prema zahtevu 1 ili 2, pri čemu je FSH ili njegova varijanta prisutan u koncentraciji od 10 do 200 μg/ml.
4.Tečni farmaceutski preparat prema bilo kom od prethodnih zahteva, koji dalje obuhvata metionin kao antioksidant.
5.Tečni farmaceutski preparat prema bilo kom od prethodnih zahteva, koji dalje obuhvata površinski aktivno sredstvo.
6.Tečni farmaceutski preparat prema zahtevu 5, pri čemu je površinski aktivno sredstvo polioksietilen sorbitan alikilestar.
7.Tečni farmaceutski preparat prema bilo kom od prethodnih zahteva, koji dalje obuhvata agens modifikovanja toničnosti.
8.Tečni farmaceutski preparat prema zahtevu 7, pri čemu je agens modifikovanja toničnosti šećerni alkohol ili šećer.
9.Tečni farmaceutski preparat prema bilo kom od prethodnih zahteva, koji ima pH u rasponu od 6.5 do 7.5.
10.Tečni farmaceutski preparat prema bilo kom od prethodnih zahteva, koji dalje obuhvata fiziološki prihvatljiv agens puferisanja.
11.Tečni farmaceutski preparat prema bilo kom od prethodnih zahteva, pri čemu preparat sadrži FSH ili njegovu varijantu kao aktivni agens, Polisorbat 20 i/ili Polisorbat 80 kao površinski aktivno sredstvo, manitol kao agens modifikovanja toničnosti, fosfat kao pufer, metionin kao stabilizujući agens i benzil alkohol i benzalkonijum hlorid kao sredstva za čuvanje, i ne sadrži dodatne nosače.
12.Farmaceutski kontejner koji sadrži tečni farmaceutski preparat prema bilo kom od predhodnih zahteva.
13.Postupak za pripremanje tečnog farmaceutskog preparata prema bilo kom od zahteva 1 do 11, gde je FSH ili njegova varijanta kao aktivni sastojak formulisan u vodenom preparatu koji obuhvata i benzalkonijum hlorid i benzil alkohol kao sredstva za čuvanje i dodatne farmaceutske nosače.
14.Postupak proizvodnje pakovanog farmaceutskog preparata koji obuhvata stavljanje rastvora koji obuhvata FSH ili njegovu varijantu i benzalkonijum hlorid i benzil alkohol u vijal, ampulu, karpulu ili kasetu.
15.Tečni farmaceutski preparat prema bilo kom od zahteva 1 do 11 za upotrebu u više-doznom davanju.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08151231 | 2008-02-08 | ||
| PCT/EP2009/051451 WO2009098318A1 (en) | 2008-02-08 | 2009-02-09 | Liquid formulation of fsh |
| EP09708298A EP2249869B1 (en) | 2008-02-08 | 2009-02-09 | Liquid formulation of fsh |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME01337B true ME01337B (me) | 2013-12-20 |
Family
ID=40568186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2011-182A ME01337B (me) | 2008-02-08 | 2009-02-09 | Tečni preparat fsh |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US20110054410A1 (me) |
| EP (2) | EP2249869B1 (me) |
| JP (1) | JP5620824B2 (me) |
| KR (2) | KR101573773B1 (me) |
| CN (3) | CN110433136A (me) |
| AT (1) | ATE523209T1 (me) |
| AU (1) | AU2009211331B2 (me) |
| BR (1) | BRPI0908887B8 (me) |
| CA (2) | CA2926500A1 (me) |
| CY (1) | CY1112082T1 (me) |
| DE (1) | DE202009009905U1 (me) |
| DK (1) | DK2249869T3 (me) |
| EA (1) | EA019530B1 (me) |
| ES (1) | ES2372470T3 (me) |
| HR (1) | HRP20110801T1 (me) |
| IL (1) | IL206759A (me) |
| ME (1) | ME01337B (me) |
| MX (1) | MX2010008802A (me) |
| NZ (1) | NZ586588A (me) |
| PL (1) | PL2249869T3 (me) |
| PT (1) | PT2249869E (me) |
| RS (1) | RS52106B (me) |
| SI (1) | SI2249869T1 (me) |
| UA (1) | UA99337C2 (me) |
| WO (1) | WO2009098318A1 (me) |
| ZA (1) | ZA201004457B (me) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101105871B1 (ko) * | 2005-09-27 | 2012-01-16 | 주식회사 엘지생명과학 | 인 난포자극호르몬의 안정한 용액 제형 |
| EP3677275B1 (de) | 2008-10-17 | 2024-06-12 | Sanofi-Aventis Deutschland GmbH | Kombination von einem insulin und einem glp-1-agonisten |
| PL2498802T3 (pl) | 2009-11-13 | 2015-06-30 | Sanofi Aventis Deutschland | Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę |
| ES2965209T3 (es) | 2009-11-13 | 2024-04-11 | Sanofi Aventis Deutschland | Composición farmacéutica que comprende desPro36exendina-4(1-39)-Lys6-NH2 y metionina |
| JP5800527B2 (ja) * | 2010-03-30 | 2015-10-28 | 日東電工株式会社 | 安定化医薬組成物、安定化医薬組成物溶液製剤、フィルム状製剤及びフィルム状製剤の製造方法 |
| AR081755A1 (es) * | 2010-04-02 | 2012-10-17 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo |
| EP2417982A1 (en) * | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilization of gonadotropins |
| JP6199186B2 (ja) | 2010-08-30 | 2017-09-20 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ２型糖尿病の治療用の医薬の製造のためのａｖｅ００１０の使用 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| TWI608847B (zh) | 2011-08-29 | 2017-12-21 | 賽諾菲阿凡提斯德意志有限公司 | 用於控制糖尿病二型病患血糖的醫藥組合物 |
| AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
| EP2775858A1 (en) * | 2011-11-09 | 2014-09-17 | Adisseo France S.A.S. | Pre-slaughter diet including methionine |
| US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| ES2949095T3 (es) | 2014-12-12 | 2023-09-25 | Sanofi Aventis Deutschland | Formulación de relación fija de insulina glargina/lixisenatida |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| CN105727260A (zh) * | 2016-02-03 | 2016-07-06 | 华侨大学 | 一种卵泡刺激素的长效制剂 |
| GB201603280D0 (en) | 2016-02-24 | 2016-04-13 | Ferring Bv | Stable liquid gonadotropin formulation |
| CN105726468A (zh) * | 2016-02-28 | 2016-07-06 | 中国农业科学院特产研究所 | 梅花鹿用超数排卵聚乙烯吡咯烷酮fsh复合缓释注射剂 |
| US10085971B2 (en) * | 2016-08-22 | 2018-10-02 | Navinta Iii Inc | Pharmaceutical solution of asenapine for sublingual or buccal use |
| CN108728465A (zh) * | 2017-04-14 | 2018-11-02 | 深圳新诺微环生物科技有限公司 | 一种表达靶细胞-效应细胞桥接器的微环dna载体及其制备方法和应用 |
| US20230364172A1 (en) * | 2022-05-14 | 2023-11-16 | Syncotrance, LLC | Modulation of solubility, palatability, absorption, and bioavailability of mitragyna speciosa-derived compounds for oral and buccal delivery |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4840896A (en) | 1983-11-02 | 1989-06-20 | Integrated Genetics, Inc. | Heteropolymeric protein |
| US4923805A (en) | 1983-11-02 | 1990-05-08 | Integrated Genetics, Inc. | Fsh |
| IT1206302B (it) | 1987-06-26 | 1989-04-14 | Serono Cesare Ist Ricerca | Ormone follicolo-stimolante urinario |
| US5763394A (en) * | 1988-04-15 | 1998-06-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
| CA2018676C (en) | 1989-06-20 | 2003-05-06 | Christie A. Kelton | Novel heteropolymeric protein production methods |
| DE4126983A1 (de) * | 1991-08-15 | 1993-02-18 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke |
| DE4440587A1 (de) | 1994-11-14 | 1996-05-15 | Fliether Karl Gmbh & Co | Basquill-Schloß |
| IL122732A0 (en) * | 1997-01-15 | 1998-08-16 | Akzo Nobel Nv | Liquid gonadotropin-containing formulation its preparation and a device containing same |
| CA2293731C (en) | 1997-06-25 | 2010-01-12 | Applied Research Systems Ars Holding N.V. | Disulfide cross-linking glycoprotein hormone analogs, and their preparation and use |
| CN1309567A (zh) * | 1998-07-23 | 2001-08-22 | 伊莱利利公司 | Fsh和fsh变体制剂,产品和方法 |
| US20030166525A1 (en) * | 1998-07-23 | 2003-09-04 | Hoffmann James Arthur | FSH Formulation |
| BRPI0010677B8 (pt) | 1999-04-16 | 2021-05-25 | Inst Massone S A | processo de purificação de gonadotropinas urinárias humanas a partir de gonadotropinas brutas. |
| AU2001231531A1 (en) | 2000-02-11 | 2001-08-20 | Maxygen Aps | Follicle stimulating hormones |
| DE10249817A1 (de) | 2002-10-24 | 2004-05-13 | Daimlerchrysler Ag | Schaltanordnung zur Betätigung von Beleuchtungssystemen an einem Kraftfahrzeug |
| MXPA05010635A (es) | 2003-04-02 | 2005-12-12 | Ares Trading Sa | Formulaciones farmaceuticas liquidas de hormona estimulante de foliculos y hormona luteinizante junto con un surfactante no ionico. |
| UA90664C2 (ru) | 2003-12-22 | 2010-05-25 | Ейрес Трейдінг С.А. | Способ очистки fsh |
| BRPI0517973B8 (pt) | 2004-11-09 | 2021-05-25 | Ares Trading Sa | métodos para purificar o fsh recombinante |
| KR101105871B1 (ko) | 2005-09-27 | 2012-01-16 | 주식회사 엘지생명과학 | 인 난포자극호르몬의 안정한 용액 제형 |
| US8318457B2 (en) | 2007-06-28 | 2012-11-27 | Biogenerix Ag | FSH producing cell clone |
-
2009
- 2009-02-09 MX MX2010008802A patent/MX2010008802A/es unknown
- 2009-02-09 RS RS20110505A patent/RS52106B/sr unknown
- 2009-02-09 EP EP09708298A patent/EP2249869B1/en active Active
- 2009-02-09 HR HR20110801T patent/HRP20110801T1/hr unknown
- 2009-02-09 AU AU2009211331A patent/AU2009211331B2/en active Active
- 2009-02-09 ME MEP-2011-182A patent/ME01337B/me unknown
- 2009-02-09 AT AT09708298T patent/ATE523209T1/de active
- 2009-02-09 NZ NZ586588A patent/NZ586588A/xx not_active IP Right Cessation
- 2009-02-09 JP JP2010545495A patent/JP5620824B2/ja active Active
- 2009-02-09 ES ES09708298T patent/ES2372470T3/es active Active
- 2009-02-09 PT PT09708298T patent/PT2249869E/pt unknown
- 2009-02-09 BR BRPI0908887A patent/BRPI0908887B8/pt active IP Right Grant
- 2009-02-09 SI SI200930091T patent/SI2249869T1/sl unknown
- 2009-02-09 CN CN201910216104.9A patent/CN110433136A/zh active Pending
- 2009-02-09 DK DK09708298.6T patent/DK2249869T3/da active
- 2009-02-09 KR KR1020107018371A patent/KR101573773B1/ko active Active
- 2009-02-09 CA CA2926500A patent/CA2926500A1/en not_active Abandoned
- 2009-02-09 PL PL09708298T patent/PL2249869T3/pl unknown
- 2009-02-09 US US12/866,736 patent/US20110054410A1/en not_active Abandoned
- 2009-02-09 UA UAA201010809A patent/UA99337C2/ru unknown
- 2009-02-09 DE DE202009009905U patent/DE202009009905U1/de not_active Expired - Lifetime
- 2009-02-09 CN CN2009801040855A patent/CN101970010A/zh active Pending
- 2009-02-09 CN CN201510082820.4A patent/CN104688679A/zh active Pending
- 2009-02-09 EA EA201070940A patent/EA019530B1/ru not_active IP Right Cessation
- 2009-02-09 EP EP11179767A patent/EP2412385A1/en not_active Withdrawn
- 2009-02-09 KR KR1020157033736A patent/KR101662631B1/ko active Active
- 2009-02-09 CA CA2713386A patent/CA2713386C/en not_active Expired - Fee Related
- 2009-02-09 WO PCT/EP2009/051451 patent/WO2009098318A1/en not_active Ceased
-
2010
- 2010-06-24 ZA ZA2010/04457A patent/ZA201004457B/en unknown
- 2010-07-01 IL IL206759A patent/IL206759A/en active IP Right Grant
-
2011
- 2011-11-24 CY CY20111101150T patent/CY1112082T1/el unknown
-
2016
- 2016-06-29 US US15/196,460 patent/US20160303202A1/en not_active Abandoned
- 2016-06-29 US US15/196,430 patent/US20160303201A1/en not_active Abandoned
- 2016-06-29 US US15/196,440 patent/US20160303238A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME01337B (me) | Tečni preparat fsh | |
| JP7520285B2 (ja) | 高眼圧症及び緑内障を治療するための方法及び組成物 | |
| US9012503B2 (en) | Ophthalmic composition | |
| CA2341568C (en) | Stabilized pharmaceutical composition in lyophilized form | |
| JP2021035984A (ja) | ポビドンヨード、眼科用組成物のための新規代替保存剤 | |
| KR101586357B1 (ko) | 바람직한 생체이용률을 갖는 약제학적 조성물 | |
| RU2010121165A (ru) | Составы паратиреоидного гормона и их применение | |
| AU2003281154A1 (en) | Injectable depot formulation comprising cyrstals of iloperidone | |
| JP6516831B2 (ja) | シクロホスファミド液状濃縮物の製剤 | |
| JP2023058566A (ja) | 安定なペプチド組成物 | |
| CZ20021014A3 (cs) | Nová kombinace loteprednolu a antihistaminik | |
| KR20080085194A (ko) | Ｔｍｃ２７８을 이용한 ｈｉｖ 감염의 장기간 요법 | |
| CN102014920B (zh) | 滴眼剂制剂及其应用 | |
| JP2011093923A (ja) | 点眼剤 | |
| CA3035566A1 (en) | Ophthalmic compositions | |
| JP2011057717A (ja) | イソプロピルウノプロストンの分解抑制方法 | |
| WO2013108180A1 (en) | Aqueous paracetamol composition for injection | |
| RU2323738C1 (ru) | Лекарственное средство для лечения вирусных и иных инфекций | |
| JP2020015683A (ja) | 眼科用組成物及び析出抑制方法 | |
| JP2005075735A (ja) | オキシメタゾリン含有組成物 | |
| JPWO2002017932A1 (ja) | Ｏｃｔ製剤 | |
| JP2017066033A (ja) | 水性医薬組成物 | |
| JP6050454B1 (ja) | 水性医薬組成物 | |
| WO2019176239A1 (ja) | 容器充填ヒトｐｔｈ（１－３４）液体医薬組成物及びその製造方法 | |
| US20240156833A1 (en) | Aqueous pharmaceutical compositions of prostaglandins |